Status | Study |
Active, not recruiting |
Study Name: A Safety Study of SGN-CD19A for Leukemia and Lymphoma Condition: Burkitt Lymphoma Precursor B-cell Lymphoblastic Leukemia-Lymphoma Date: 2013-02-05 Interventions: Drug: SGN-CD19A SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/ |
Active, not recruiting |
Study Name: A Safety Study of SGN-CD19A for B-Cell Lymphoma Condition: Burkitt Lymphoma Lymphoma, Follicular Lymphoma, Large B-Ce Date: 2013-02-05 Interventions: Drug: SGN-CD19A SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks) |
Terminated |
Study Name: Acute Lymphoblastic Leukemia Registry at Asan Medical Center Condition: Leukemia, Acute Lymphoblastic Precursor B-Cell Lymphoblastic Leukemia Date: 2013-01-03 Interventions: Other: Diagnosed as ALL All patients who will be enrolled in this prospective registry are confined to t |
Terminated |
Study Name: A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL Condition: Acute Lymphoblastic Leukemia Precursor B-Cell Lymphoblastic Leukemia Date: 2011-11-29 Interventions: Drug: Decitabine 10 mg/m2/day |
Active, not recruiting |
Study Name: Repeat-dose Study of Lenalidomide (Revlimid ®) Plus Dexamethasone in Patients With Lymphoblastic Leukemia Condition: Leukemia, Lymphoid Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Date: 2010-04-26 Interventions: Drug: Lenalidomide plus dexamethasone Lenalidomide 25 mg p.o. once daily on days 1-21 plus Dexamethasone |
Terminated |
Study Name: Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Condition: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Acute Lymphobl Date: 2009-05-15 Interventions: Drug: Nilotinib 400mg, Oral, Bid, Daily for three years |
Completed |
Study Name: Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) Condition: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Myel Date: 2009-03-17 Interventions: Biological: Hematopoietic Umbilical Cord Blood Stem Cell Transplantation |
Completed |
Study Name: Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) Condition: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Myel Date: 2009-02-20 Interventions: Biological: Haploidentical Bone Marrow Transplantation |
Completed |
Study Name: Coproporphyrine Isomers and Methotrexate Elimination Condition: Central Nervous System Neoplasms Lymphoma, Large B-Cell, Diffuse Date: 2009-01-13 |